<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082186</url>
  </required_header>
  <id_info>
    <org_study_id>AC-052-402</org_study_id>
    <nct_id>NCT00082186</nct_id>
  </id_info>
  <brief_title>The Effect of Tracleer® on Male Fertility</brief_title>
  <official_title>TRACLEER® (Bosentan) Pulmonary Arterial Hypertension A Multicenter, Open-label, Single-arm Safety Study to Investigate the Effects of Chronic TRACLEER® Treatment on Testicular Function in Male Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effects of chronic TRACLEER® treatment on
      testicular function via semen analysis in male patients with primary pulmonary arterial
      hypertension (PAH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a mean decrease in sperm concentration to 7.5 x 10[6]/mL or below, without a single sperm concentration ≥ 20 x 10[6]/mL, at 3 or 6 months. This proportion is considered of clinical relevance if greater than 30%.</measure>
    <time_frame>From baseline to end of study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Semen volume, sperm motility and sperm morphology change</measure>
    <time_frame>From baseline to 3 &amp; 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral bosentan tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tracleer (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients age 18-65 years.

          -  Bosentan-naïve.

          -  PPH, WHO functional class III/IV, in need of TRACLEER

          -  Patients pulmonary arterial hypertension (PAH) secondary to congenital heart disease.

          -  Written informed consent.

        Exclusion Criteria:

          -  Female

          -  Patients with PAH secondary to connective tissue vascular diseases or HIV.

          -  Patients who have undergone a vasectomy.

          -  Patients with an average baseline sperm concentration &lt; 15 x 10[6]/mL, or any sample
             with a sperm concentration &lt;= 7.5 x 10[6]/mL.

          -  Patients with an average baseline sperm motility &lt;20% or normal sperm morphology &lt;5%.

          -  Body weight &lt; 50 kg.

          -  Hypotension, defined as systolic blood pressure less than 85 mm Hg.

          -  AST and/or ALT plasma levels greater than 3 times ULN.

          -  Hypersensitivity to bosentan or any of the components of the formulation.

          -  Treatment with glyburide, cyclosporine A or tacrolimus at inclusion or planned during
             the study.

          -  Treatment with hormone suppressive agents, including androgens, estrogens, anabolic
             steroids or glucocorticoids within the past 6 months or planned during the study.

          -  Current treatment less than 3 months prior to inclusion or planned treatment with
             prostacyclin or prostacyclin analogues (e.g., Flolanâ or Remodulin).

          -  Patients who received an investigational drug in the month preceding the study start
             or who are due to be treated with another investigational drug during the study
             period.

          -  Known drug or alcohol dependence or any other factors that will interfere with conduct
             of the study.

          -  Any illness other than PPH that will reduce life expectancy to less than 6 months.

          -  Active cancer.

          -  Prior treatment with an anti-neoplastic agent or ionizing radiation.

          -  Hot tub/Jacuzzi use.

          -  Uncontrolled diseases including diabetes, liver or kidney disease.

          -  Patients receiving spironolactone (aldactone) less than 3 months prior to inclusion or
             dose &gt;25 mg/day at baseline or anytime during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Lauer, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Actelion Pharmaceuticals US, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Rainisio, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic Bodin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-1300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3784</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Internal Cardiology Clinic</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Congenital Heart Disease in Adults</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Koranyi Institute of Pulmonology</name>
      <address>
        <city>Budapest</city>
        <zip>1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=TRACLEER</url>
    <description>Tracleer approval page at Drugs@FDA.gov</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2004</study_first_submitted>
  <study_first_submitted_qc>May 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2004</study_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andrea Lauer, PhD</name_title>
    <organization>Actelion</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

